for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sosei Group Corporation

4565.T

Latest Trade

2,283.00JPY

Change

15.00(+0.66%)

Volume

953,400

Today's Range

2,243.00

 - 

2,283.00

52 Week Range

748.00

 - 

2,794.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,268.00
Open
2,258.00
Volume
953,400
3M AVG Volume
38.46
Today's High
2,283.00
Today's Low
2,243.00
52 Week High
2,794.00
52 Week Low
748.00
Shares Out (MIL)
76.99
Market Cap (MIL)
172,465.50
Forward P/E
86.13
Dividend (Yield %)
--

Next Event

Dividend For 4565.T - 0.0000 JPY

Latest Developments

More

Sosei Heptares And Takeda Enter Into New Partnership

Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA

Sosei Group Says Sosei Heptares To Get US$15 Mln Milestone Payment From Astrazeneca

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sosei Group Corporation

Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Industry

Biotechnology & Drugs

Contact Info

11F, PMO Hanzomon, 2-1, Koji-machi

+81.3.52103290

https://www.soseiheptares.com/

Executive Leadership

Shinichi Tamura

Chairman of the Board, Representative Executive Officer, President, Chief Executive Officer

Chris Cargill

Executive Vice President, Chief Financial Officer

Kazuhiko Yoshizumi

Executive Vice President, Group Chief Compliance Officer

Tim Tasker

Executive Vice President, Chief Medical Officer

Malcolm Weir

Executive Vice President, Chief R & D Officer

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (JPY)

2016

-374.400

2017

2,319.880

2018

-75.510

2019(E)

26.009
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.31
Price To Book (MRQ)
4.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.29
LT Debt To Equity (MRQ)
9.78
Return on Investment (TTM)
-7.60
Return on Equity (TTM)
-6.98

Latest News

Latest News

BRIEF-Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA

* SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY

BRIEF-Sosei Group to issue 2.1 mln new shares

* Says it plans to issue 2.1 million new shares through overseas offering

BRIEF-Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)

* Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB)

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

* Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

BRIEF-Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln

* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa Laboratories, Inc, for $3.5 million

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with...

BRIEF- Sosei Group unit Heptares to receive $5 million milestone

* Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist, discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd has triggered a $5 million payment from Teva to Heptares under the terms...

BRIEF-Sosei Group unit signs investment agreement with MiNA

* Says co's wholly owned subsidiary Sosei R&D Limited signs an investment agreement with MiNA (Holdings) Limited, which is the holding company of UK-based bio-medical firm MiNA Therapeutics Limited

BRIEF-Sosei Group unit Heptares receives $12 mln milestone payment

* Says unit Heptares received milestone payment of $12 million from AstraZeneca, on small molecule A2A antagonist AZD4635 (HTL-1071)

BRIEF-Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.

* Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13

BRIEF-Sosei Group appoints Andrew Oakley as CFO

Sosei Group Corp : * Says it appoints Andrew Oakley as new CFO * Says effective date will be Feb. 1 Source text in Japanese: https://goo.gl/J19UjV Further company Coverage: (Beijing Headline News)

BRIEF-Sosei Group subsidiary starts medicine joint development with JITSUBO CO LTD

* Says its subsidiary, Heptares Therapeutics, has started the joint development of medicine for gastrointestinal tract disturbance treatment, with JITSUBO CO LTD

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up